YME-B: Received milestone payment for authorization and collaboration with AXION BIO.

Yiming Angko-B announcement, since signing the authorization and collaboration agreement with AXION BIO on August 1, 2024, the company has received a milestone payment of $10 million from Instil. As of the date of this announcement, the total amount received in payments under the agreement has reached $30 million, demonstrating ongoing progress and commitment with Instil. IMM2510/AXN-2510 is a dual-specificity antibody targeting PD-L1 and VEGF, currently being developed for the treatment of various solid tumor cancers.